numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics
24.3.2021 14:00:00 EET | Business Wire | Press release
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, refined by numares' proprietary Magnetic Group SignalingTM, allows metabolomics-based precision diagnostics by implementation of various numares' tests, e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR) and risk for cardiovascular disease (CVD). (Photo: Business Wire)
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares," said Winton Gibbons, President - US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System. These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
Contact information
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail:
christiane.proll@numares.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BMC TV expands UK network for major sports broadcasts with Adtran and Fibre Technologies Ltd15.9.2026 15:00:00 EEST | Press release
Adtran today announced that BMC TV has expanded its UK core network, harnessing Adtran technology to support coverage of major events, including the FIFA World Cup and extensive racecourse broadcasting across the UK. The new infrastructure strengthens BMC TV’s packet edge, access and aggregation layers, enabling reliable distribution of live feeds across multiple locations with deterministic, low-latency performance. Designed to scale with growing broadcast demands, the network also provides a clear route to future 400Gbit/s services. The deployment was delivered in partnership with Fibre Technologies Ltd, which led solution design, commercial engagement and implementation support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915498940/en/ Adtran’s technology is helping BMC TV expand its core network to deliver live sporting events across the UK. “Live sports coverage places intense and constantly changing demands on ou
Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner15.9.2026 15:00:00 EEST | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/ As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies to the development of future SharkNinja products. “McLaren is one of the most decorated teams in motorsport history, built on a legacy of innovation, technical excellence, and performance at the highest level," said Mark Barrocas, Chief Executive Officer
The LYCRA Company Appoints Hua Du as Chief Executive Officer15.9.2026 15:00:00 EEST | Press release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that Hua Du has been appointed chief executive officer, effective September 14, as the company enters its next chapter following the successful completion of its financial restructuring. Du succeeds Dean Williams, who served as interim chief executive officer and will continue in his role as chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915565505/en/ The LYCRA Company Appoints Hua Du as Chief Executive Officer. With 30 years of leadership experience in the specialty chemical and biotechnology industries, Du is well positioned to lead the company into its next chapter. Du brings 30 years of leadership experience in the specialty chemical and biotech-based industries, driving transformational growth across global businesses. Du most recently served as CEO of
Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies15.9.2026 15:00:00 EEST | Press release
Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO® platform into a commercial cell therapy manufacturing process in a deal valued at up to $120M in services, milestones, equipment and consumable purchases over the next 10 years. The collaboration is designed to modernize the partner’s autologous cell therapy manufacturing infrastructure with the aim of expanding patient access to current and future potentially transformative cell therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915757436/en/ The IRO platform Autologous cell therapies, manufactured from a patient's own cells, require precise, reliable and scalable manufacturing processes. Meeting that requirement is essential to sustaining commercial availability and to rapidly bringing the next generation of
Riskified Brings Identity Risk Intelligence to Zendesk, Helping Retailers Stop Returns Fraud Without Sacrificing Customer Experience15.9.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today announced a new partnership with Zendesk that brings its Identity Risk Intelligence directly into Zendesk’s customer service workflow. The integration gives human and AI support agents real-time signals, helping retailers resolve legitimate claims faster while curbing returns and refund abuse that drains revenue. According to the National Retail Federation, U.S. retailers saw $849.9 billion in returns in 2025, approximately 9% of which were fraudulent. Based on those figures, Riskified calculates that return fraud costs U.S. retailers approximately $76.5 billion, and the losses are far higher when accounting for global returns fraud. Shoppers admit it too: one in four acknowledge wardrobing or bracketing, and roughly one in five admits to decoy returns, empty-box returns, or label tampering. For customer service teams, every claim carries the same dilemma: honor it and risk rewarding abuse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom